CytoCore Inc. (OTCBB:CYOE), the biopharmaceutical research and
medical device company for early detection and treatment of
reproductive-tract cancers, announced today its first order and
shipment of SoftPAP(TM) cell collectors to Palex Medical SA.
Palex Medical SA, a leading medical equipment and solutions
distributor to the Spanish hospital market based in Sant Cugat del
Valles (Barcelona), Spain will be the second company in Europe to
launch CytoCore´s SoftPAP(TM) cervical cell collector, a device
designed to enhance patient comfort and safety while improving the
quality of cervical cell specimens for Pap testing. With Palex as
distributor, Spain is the second country in Europe to receive the
SoftPAP Collector.
"We are very pleased to be introducing this important new product
to our Spanish medical market," says Xavier Carbonell, Deputy
President of Palex Medical. "The Collector´s combination of improved
patient comfort, ease of use and more reliable test results represents
a significant advance in women´s health. We are very interested in
CytoCore and its product line. There are several CytoCore products
under development that we believe represent opportunities for our
markets and clients, and we are looking forward to expanding our
relationship with CytoCore."
SoftPAP is designed to collect a full 360 degree specimen from
both the cervical canal and the outer surface of the cervix
simultaneously resulting in a more complete and comprehensive specimen
for Pap testing. Clinical studies have shown that SoftPAP collects a
better quality specimen while reducing adverse events, primarily
bleeding and spotting, by 95%.
"SoftPAP is a vast improvement over the current method which
involves specimen collection using a wooden or plastic spatula and
cervical brush," says Dick Domanik, Ph.D., President and COO of
CytoCore.
About Palex Medical, SA
Palex is a leading company in the hospital sector whose priority
goal is to understand and satisfy the needs of health professionals
and managers. To achieve this goal, it provides advanced, efficient
hospital solutions with products, systems, technologies and health
services grounded on knowledge and experience, and also by
establishing distribution agreements with leading international
manufacturers. http://www.palexmedical.com/english/index.php
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which
can be utilized in a laboratory or at the point-of-care, to assist in
the early detection of cervical, endometrial, and other cancers. The
CytoCore Solutions(TM) System is being developed to provide medical
practitioners with highly accurate, low-cost, cervical and uterine
cancer screening systems that can be seamlessly integrated into
existing medical models. More information is available at:
www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These
statements are based on CytoCore´s current expectations and involve
many risks and uncertainties, such as the company´s inability to
obtain sufficient financing, the possibility that clinical trials will
not substantiate CytoCore´s expectations with respect to the CytoCore
Solutions(TM) System, and other factors set forth in reports and
documents filed by CytoCore with the Securities and Exchange
Commission. Actual results may differ materially from CytoCore´s
current expectation depending upon a number of factors affecting the
Company´s business. These factors include, among others, risks and
uncertainties detailed in the Company´s periodic public filings with
the Securities and Exchange Commission, including but not limited to
the Company´s Annual Report on Form 10-K for the year ended December
31, 2006. Except as expressly required by law, CytoCore undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.
